Its counterpart, CDCA7, exhibits high expression during the blast crisis phase of chronic myelogenous leukemia, and transgenic mice overexpressing CDCA7 are at a significantly increased risk of developing lymphoid malignancies. This evidence concerns the gene CDCA7 and chronic myelogenous leukemia, BCR-ABL1 positive.